Hamostaseologie最新文献

筛选
英文 中文
Laboratory Monitoring in Patients Receiving Emicizumab. 接受Emicizumab患者的实验室监测。
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-10-09 DOI: 10.1055/a-2687-0107
Jens Müller, Martin Büchsel, Olga Oleshko, Behnaz Pezeshkpoor, Ulrich Sachs, Ute Scholz, Andreas Tiede
{"title":"Laboratory Monitoring in Patients Receiving Emicizumab.","authors":"Jens Müller, Martin Büchsel, Olga Oleshko, Behnaz Pezeshkpoor, Ulrich Sachs, Ute Scholz, Andreas Tiede","doi":"10.1055/a-2687-0107","DOIUrl":"https://doi.org/10.1055/a-2687-0107","url":null,"abstract":"<p><p>Emicizumab is a bispecific monoclonal antibody that mimics the cofactor function of activated factor VIII (FVIIIa). It is approved for routine prophylaxis in patients with severe or moderate congenital hemophilia A (HA), both with and without FVIII inhibitors, and is increasingly used as a first-line treatment in acquired HA (AHA). Owing to its predictable pharmacokinetic profile, emicizumab monitoring is generally limited to cases with suspected reduced efficacy, such as due to poor adherence or the development of anti-drug antibodies (ADAs). However, emicizumab interferes with standard clotting assays, particularly by shortening activated partial thromboplastin times (APTT). To address this, modified FVIII one-stage clotting assays (mOSA), which use higher sample pre-dilution and emicizumab-specific calibration, are commonly employed to estimate plasma levels, although other assay formats like emicizumab-calibrated chromogenic substrate assays based on human factors or liquid chromatography tandem mass spectrometry are also available. Additionally, global assays such as in vitro thrombin generation testing are being explored to better reflect clinical hemostatic efficacy. This review summarizes current knowledge on assay interferences caused by emicizumab, challenges in functional measurement of plasma levels, and strategies to ensure reliable laboratory assessment. We also discuss the relevance and methods for ADA detection and provide an overview of current and emerging strategies for thrombin generation measurement as a global indicator of treatment effectiveness.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145259824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance Evaluation of Different FIX Activity Assays for Determining Nonacog Beta Pegol (N9-GP, Refixia®) Activity Using Reagent-/Platform-Specific Conversion Factors. 使用试剂/平台特定转换因子测定Nonacog Beta Pegol (N9-GP, Refixia®)活性的不同FIX活性测定法的性能评估
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-29 DOI: 10.1055/a-2599-9908
Christian Irsara, Andrea Griesmacher, Bernhard Strasser, Axel Schlagenhauf, Christina Sorschag, Erich Wimmer, Florian Prüller, Janne Cadamuro, Johannes Radek, Josef Tomasits, Josef Seier, Peter Fraunberger, Peter Quehenberger, Gerald Lirk, Sabine Sussitz-Rack, Sylvia Mink, Alexander Haushofer
{"title":"Performance Evaluation of Different FIX Activity Assays for Determining Nonacog Beta Pegol (N9-GP, Refixia®) Activity Using Reagent-/Platform-Specific Conversion Factors.","authors":"Christian Irsara, Andrea Griesmacher, Bernhard Strasser, Axel Schlagenhauf, Christina Sorschag, Erich Wimmer, Florian Prüller, Janne Cadamuro, Johannes Radek, Josef Tomasits, Josef Seier, Peter Fraunberger, Peter Quehenberger, Gerald Lirk, Sabine Sussitz-Rack, Sylvia Mink, Alexander Haushofer","doi":"10.1055/a-2599-9908","DOIUrl":"https://doi.org/10.1055/a-2599-9908","url":null,"abstract":"<p><p>Nonacog beta pegol (N9-GP) is a glycoPEGylated FIX replacement product with extended half-life for treatment of haemophilia B patients. Monitoring of N9-GP with clotting-based one-stage FIX assays is complicated by high variations, mainly due to reagent-specific interference with polyethylene glycol.In 11 distinct specialized coagulation laboratories in Austria, N9-GP spiked samples were measured in replicates in two distinct surveys, 3 years apart, using five different one-stage assay reagents and one chromogenic FIX assay. Regression analysis was used to investigate if back-calculation of N9-GP levels is feasible.We could demonstrate a linear relationship between the spiked N9-GP concentration and measured FIX activity levels for all examined assays, suggesting that N9-GP activity may be back-calculated using reagent-/platform-specific conversion factors. Within-laboratory variation after 3 years was acceptable in most, but not all, laboratories.We demonstrate that back-calculation of N9-GP activity levels may be possible when using one-stage FIX assays. However, we recommend that every laboratory ascertain its own conversion factor. When measuring real patient samples, we encourage simultaneous measurement of N9-GP spiked control material with known concentrations to ensure the validity of the current back-calculation.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144979005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Major Bleeding and In-Hospital Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes. 急性冠脉综合征患者经皮冠状动脉介入治疗后大出血与院内主要不良心血管事件的关系
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-14 DOI: 10.1055/a-2663-7161
Özkan Bekler, Alparslan Kurtul, Emirhan Hancıoğlu, Süleyman Diren Kazan, Fatih Şen
{"title":"Association Between Major Bleeding and In-Hospital Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes.","authors":"Özkan Bekler, Alparslan Kurtul, Emirhan Hancıoğlu, Süleyman Diren Kazan, Fatih Şen","doi":"10.1055/a-2663-7161","DOIUrl":"https://doi.org/10.1055/a-2663-7161","url":null,"abstract":"<p><p>Major bleeding (MB) is a serious complication in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). Although its association with long-term adverse outcomes is well documented, the impact of in-hospital MB on early cardiovascular prognosis remains incompletely characterized.To investigate the association between in-hospital MB and major adverse cardiovascular events (MACE) in patients with ACS treated with PCI.We conducted a retrospective cohort study on 829 consecutive ACS patients who underwent successful PCI between January 2021 and December 2023. MB was defined as Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding events. MACE was defined as a composite of all-cause mortality, recurrent myocardial infarction, ischemic stroke, urgent target vessel revascularization, or new-onset/decompensated heart failure with left ventricular ejection fraction (LVEF) <30%. Clinical data and outcomes were extracted from hospital records and independently adjudicated.MB occurred in 4.5% of patients (<i>n</i> = 37). The incidence of in-hospital MACE was significantly higher among patients with MB compared to those without (40.5% vs. 8.1%, <i>p</i> < 0.001). In multivariate logistic regression, MB was the strongest independent predictor of in-hospital MACE (OR: 12.43, 95% CI: 3.43-44.98, <i>p</i> < 0.001), followed by reduced LVEF (OR per % increase: 0.794, 95% CI: 0.747-0.843, <i>p</i> < 0.001), age, and white blood cell count.In-hospital MB is a potent and independent predictor of early MACE in patients with ACS undergoing PCI. These findings emphasize the need for careful risk stratification, bleeding prevention strategies, and individualized antithrombotic management in this high-risk population.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implications of the API-CAT Trial for Extended Secondary Prophylaxis of Cancer-associated Venous Thromboembolism: Guidance from an Expert Panel. API-CAT试验对癌症相关静脉血栓栓塞的扩展二级预防的意义:专家小组的指导
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-07 DOI: 10.1055/a-2645-4927
Florian Langer, Christina Hart, Kai-Michael Klima, Sandra Marten, Katja S Mühlberg, Christian Pfrepper, Rupert Bauersachs
{"title":"Implications of the API-CAT Trial for Extended Secondary Prophylaxis of Cancer-associated Venous Thromboembolism: Guidance from an Expert Panel.","authors":"Florian Langer, Christina Hart, Kai-Michael Klima, Sandra Marten, Katja S Mühlberg, Christian Pfrepper, Rupert Bauersachs","doi":"10.1055/a-2645-4927","DOIUrl":"https://doi.org/10.1055/a-2645-4927","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) is an increasingly frequent complication of solid tumors and hematological malignancies, significantly contributing to morbidity and mortality. In patients with acute cancer-associated VTE, therapeutic anticoagulation with direct oral factor Xa inhibitors (DXIs) or low-molecular-weight heparin (LMWH) for 3 to 6 months is recommended by clinical practice guidelines based on randomized controlled trials. Although extended secondary VTE prophylaxis should be considered in patients with persisting active cancer, the type, intensity, and duration of continued anticoagulation have not been rigorously studied until recently. In non-cancer patients, low-dose DXIs (apixaban 2.5 mg BID or rivaroxaban 10 mg OD) are the preferred options to prevent recurrent VTE beyond the first 6 months of treatment. The recently published API-CAT trial compared low-dose with full-dose apixaban for extended secondary VTE prophylaxis in 1,766 patients with active cancer. Over a 12-month period, low-dose apixaban was associated with similar efficacy, but significantly improved safety compared with full-dose apixaban, with cumulative incidence rates of recurrent VTE and major or clinically relevant non-major bleeding of 2.1% versus 2.8% (adjusted subhazard ratio [sHR]: 0.76; 95% confidence interval [CI]: 0.41-1.41; <i>p</i> < 0.001 for noninferiority) and 12.1% versus 15.6% (adjusted sHR: 0.75; 95% CI: 0.58-0.97; <i>p</i> = 0<i>.</i>03 for superiority), respectively. Based on these findings, extended secondary VTE prophylaxis with low-dose DXIs, preferably apixaban 2.5 mg BID, is proposed for most patients with persisting active cancer. To facilitate informed decision-making in clinical practice, we provide an expert consensus on criteria that either justify cessation of anticoagulation or require continued full-dose anticoagulation.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144800896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent Venous Thrombosis in a Hypofibrinogenemic Patient Despite a Heterozygous Deletion of the Fibrinogen Gene Cluster and Hemizygous FGB p.Pro265Leu Variant Mimicking a Homozygous Genotype. 尽管纤维蛋白原基因簇杂合缺失和半合子FGB p.Pro265Leu变异模拟纯合子基因型,但低纤维蛋白原患者复发性静脉血栓形成
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-07 DOI: 10.1055/a-2627-2741
Sutharshini Punniyamoorthy, Eva Birgitte Leinøe, Esther Agnete Jensen, Emil Daniel Bartels, Inge Søkilde Pedersen, Mustafa Vakur Bor
{"title":"Recurrent Venous Thrombosis in a Hypofibrinogenemic Patient Despite a Heterozygous Deletion of the Fibrinogen Gene Cluster and Hemizygous FGB p.Pro265Leu Variant Mimicking a Homozygous Genotype.","authors":"Sutharshini Punniyamoorthy, Eva Birgitte Leinøe, Esther Agnete Jensen, Emil Daniel Bartels, Inge Søkilde Pedersen, Mustafa Vakur Bor","doi":"10.1055/a-2627-2741","DOIUrl":"https://doi.org/10.1055/a-2627-2741","url":null,"abstract":"<p><p>Hypofibrinogenemia is a congenital fibrinogen disorder characterized by a proportional decrease of functional and antigenic fibrinogen levels. Herein, we present a unique case illustrating the complex genotype-phenotype relationship in hypofibrinogenemia and the inability of low fibrinogen levels to counteract hypercoagulability.A 77-year-old male with factor V Leiden heterozygosity experienced surgery-related deep vein thrombosis at ages 65 and 71, along with poor wound healing and postoperative hematomas. Proportionally reduced functional and antigenic fibrinogen levels revealed hypofibrinogenemia. Whole exome sequencing identified a heterozygous fibrinogen gene cluster deletion and a hemizygous variant (p.Pro265Leu, rs6054) in the fibrinogen β (<i>FGB</i>) gene, both of which are associated with hypofibrinogenemia. The youngest son, who has noticeably higher fibrinogen levels, shares the deletion but does not carry the hemizygous <i>FGB</i> variant. This suggests that the <i>FGB</i> variant (p.Pro265Leu) contributes to a greater reduction in fibrinogen levels.This case suggests that the coexistence of thrombotic risk factors and potentially reduced thrombin clearance-resulting from low fibrinogen levels due to a fibrinogen gene cluster deletion and a hemizygous <i>FGB</i> variant-may shift the hemostatic balance toward thrombosis in a patient with moderate hypofibrinogenemia.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144800980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcome of Surgical Interventions in Patients with Haemophilia A and B Treated with Extended Half-Life (EHL) Factor Concentrates in a Single Centre. 单一中心延长半衰期(EHL)因子浓缩治疗血友病A和B患者手术干预的结果
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-07 DOI: 10.1055/a-2599-9611
Ines Vaide, Saskia Gottstein, Cornelia Kubicek-Hofmann, Ana Maria Orlovic, Robert Klamroth
{"title":"Outcome of Surgical Interventions in Patients with Haemophilia A and B Treated with Extended Half-Life (EHL) Factor Concentrates in a Single Centre.","authors":"Ines Vaide, Saskia Gottstein, Cornelia Kubicek-Hofmann, Ana Maria Orlovic, Robert Klamroth","doi":"10.1055/a-2599-9611","DOIUrl":"https://doi.org/10.1055/a-2599-9611","url":null,"abstract":"<p><p>The prevention of intraoperative bleeding in patients with haemophilia is the key to a successful surgical procedure. Daily life of patients with haemophilia A and B significantly improved with prophylaxis with extended half-life factor concentrates (EHL-FVIII and EHL-FIX). The aim of this study was to investigate the efficacy and safety of EHL factor concentrates during surgery.In a retrospective chart review all surgical interventions in our hospital in patients with haemophilia A and B treated with EHL-FVIII or EHL-FIX undergoing surgery between 2016 and 2022 were included. Patients with inhibitors against FVIII or FIX were excluded.A total of 88 surgical interventions (41 minor, 47 major) in 52 patients with haemophilia were performed. The interventions consisted of 70 surgeries in 42 patients with haemophilia A and 18 surgeries in 10 patients with haemophilia B. The replacement therapy during the surgeries was performed with four different EHL FVIII and three different EHL FIX concentrates. Bolus injections were performed directly before surgery and continued after surgery with variable intervals ranging from 8 to 48 hours. The median dose before major surgery was 32.31 IU/kg FVIII and 47.06 IU/kg FIX and before minor surgery was 27.78 IU/kg FVIII and 33.78 IU/kg factor IX. There were 11 complications including 4 bleeding complications during/after surgery. No thromboembolic event and no inhibitor against FVIII or FIX were detected during follow-up.The replacement therapy with EHL factor concentrates in surgical interventions in patients with haemophilia A and B is safe and effective.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144800897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thromboprophylaxis in Children: Navigating Uncharted Waters. 儿童血栓预防:导航未知水域。
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-01 Epub Date: 2025-04-27 DOI: 10.1055/a-2511-3364
Cornelia Heleen van Ommen
{"title":"Thromboprophylaxis in Children: Navigating Uncharted Waters.","authors":"Cornelia Heleen van Ommen","doi":"10.1055/a-2511-3364","DOIUrl":"10.1055/a-2511-3364","url":null,"abstract":"<p><p>The rising incidence of pediatric thrombosis, increasing nearly 10% annually over the past decade, underlines a need for effective preventive strategies, particularly in hospitalized children. This narrative review explores existing literature on venous thromboembolism prevention in pediatric patients to clarify current strategies in children undergoing general, orthopaedic, and Fontan surgeries, and with conditions such as acute lymphoblastic leukemia and gastrointestinal disease. While recent studies have provided some insights into potential preventive strategies, real evidence is lacking on the best practices for thromboprophylaxis in these patient groups. In the absence of substantial studies, clinicians must rely on individual assessments weighting thrombotic and bleeding risk to effectively and safely manage these \"uncharted waters.\"</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"302-311"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sulodexid: Neue Hoffnung bei retinalen Gefäßerkrankungen. 神经退行性疾病的新希望。
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-01 Epub Date: 2025-08-14 DOI: 10.1055/s-0045-1811543
{"title":"Sulodexid: Neue Hoffnung bei retinalen Gefäßerkrankungen.","authors":"","doi":"10.1055/s-0045-1811543","DOIUrl":"10.1055/s-0045-1811543","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 4","pages":"282"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thrombosen bei malignen hämatologischen Erkrankungen: Risiko für Depressionen erhöht. 血栓形成与恶性血液疾病:增加抑郁的风险。
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-01 Epub Date: 2025-08-14 DOI: 10.1055/s-0045-1811544
{"title":"Thrombosen bei malignen hämatologischen Erkrankungen: Risiko für Depressionen erhöht.","authors":"","doi":"10.1055/s-0045-1811544","DOIUrl":"10.1055/s-0045-1811544","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 4","pages":"284"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stand GOÄ-Novelle, News zur ePA (elektronische Patientenakte), Ambulante Gentherapie für die Hämophilie B. 站GOA Novel, ePA(电子患者档案)新闻,血友病B的门诊基因治疗。
IF 2.4 4区 医学
Hamostaseologie Pub Date : 2025-08-01 Epub Date: 2025-08-14 DOI: 10.1055/a-2624-2996
Jürgen Koscielny, Christoph Sucker
{"title":"Stand GOÄ-Novelle, News zur ePA (elektronische Patientenakte), Ambulante Gentherapie für die Hämophilie B.","authors":"Jürgen Koscielny, Christoph Sucker","doi":"10.1055/a-2624-2996","DOIUrl":"10.1055/a-2624-2996","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 4","pages":"359-360"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信